| pubmed-article:9060550 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9060550 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9060550 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:9060550 | lifeskim:mentions | umls-concept:C0085090 | lld:lifeskim |
| pubmed-article:9060550 | lifeskim:mentions | umls-concept:C0026251 | lld:lifeskim |
| pubmed-article:9060550 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:9060550 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:9060550 | lifeskim:mentions | umls-concept:C0205269 | lld:lifeskim |
| pubmed-article:9060550 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:9060550 | pubmed:dateCreated | 1997-3-31 | lld:pubmed |
| pubmed-article:9060550 | pubmed:abstractText | Patients with AIDS-related lymphoma usually have extensive lymphomatous disease, with relatively frequent involvement of the CNS. Approximately half may achieve complete remission after chemotherapy. Mitoguazone, an inhibitor of polyamine biosynthesis, has demonstrated efficacy in patients with de novo recurrent lymphoma. The drug is relatively nonmyelotoxic and may cross the blood-brain barrier. The current study was designed to assess the safety and potential efficacy of mitoguazone in patients with relapsed or refractory AIDS-lymphoma. | lld:pubmed |
| pubmed-article:9060550 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9060550 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9060550 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9060550 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9060550 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9060550 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9060550 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9060550 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9060550 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:9060550 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:9060550 | pubmed:author | pubmed-author:LevineA MAM | lld:pubmed |
| pubmed-article:9060550 | pubmed:author | pubmed-author:KaplanLL | lld:pubmed |
| pubmed-article:9060550 | pubmed:author | pubmed-author:WernsSS | lld:pubmed |
| pubmed-article:9060550 | pubmed:author | pubmed-author:ScaddenD TDT | lld:pubmed |
| pubmed-article:9060550 | pubmed:author | pubmed-author:NorthfeltD... | lld:pubmed |
| pubmed-article:9060550 | pubmed:author | pubmed-author:LuskeyB DBD | lld:pubmed |
| pubmed-article:9060550 | pubmed:author | pubmed-author:EspinaBB | lld:pubmed |
| pubmed-article:9060550 | pubmed:author | pubmed-author:Von HoffDD | lld:pubmed |
| pubmed-article:9060550 | pubmed:author | pubmed-author:GilesFF | lld:pubmed |
| pubmed-article:9060550 | pubmed:author | pubmed-author:SilverbergII | lld:pubmed |
| pubmed-article:9060550 | pubmed:author | pubmed-author:TulpuleAA | lld:pubmed |
| pubmed-article:9060550 | pubmed:author | pubmed-author:TessmanDD | lld:pubmed |
| pubmed-article:9060550 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9060550 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:9060550 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9060550 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9060550 | pubmed:pagination | 1094-103 | lld:pubmed |
| pubmed-article:9060550 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:9060550 | pubmed:meshHeading | pubmed-meshheading:9060550-... | lld:pubmed |
| pubmed-article:9060550 | pubmed:meshHeading | pubmed-meshheading:9060550-... | lld:pubmed |
| pubmed-article:9060550 | pubmed:meshHeading | pubmed-meshheading:9060550-... | lld:pubmed |
| pubmed-article:9060550 | pubmed:meshHeading | pubmed-meshheading:9060550-... | lld:pubmed |
| pubmed-article:9060550 | pubmed:meshHeading | pubmed-meshheading:9060550-... | lld:pubmed |
| pubmed-article:9060550 | pubmed:meshHeading | pubmed-meshheading:9060550-... | lld:pubmed |
| pubmed-article:9060550 | pubmed:meshHeading | pubmed-meshheading:9060550-... | lld:pubmed |
| pubmed-article:9060550 | pubmed:meshHeading | pubmed-meshheading:9060550-... | lld:pubmed |
| pubmed-article:9060550 | pubmed:meshHeading | pubmed-meshheading:9060550-... | lld:pubmed |
| pubmed-article:9060550 | pubmed:meshHeading | pubmed-meshheading:9060550-... | lld:pubmed |
| pubmed-article:9060550 | pubmed:meshHeading | pubmed-meshheading:9060550-... | lld:pubmed |
| pubmed-article:9060550 | pubmed:meshHeading | pubmed-meshheading:9060550-... | lld:pubmed |
| pubmed-article:9060550 | pubmed:meshHeading | pubmed-meshheading:9060550-... | lld:pubmed |
| pubmed-article:9060550 | pubmed:meshHeading | pubmed-meshheading:9060550-... | lld:pubmed |
| pubmed-article:9060550 | pubmed:meshHeading | pubmed-meshheading:9060550-... | lld:pubmed |
| pubmed-article:9060550 | pubmed:meshHeading | pubmed-meshheading:9060550-... | lld:pubmed |
| pubmed-article:9060550 | pubmed:meshHeading | pubmed-meshheading:9060550-... | lld:pubmed |
| pubmed-article:9060550 | pubmed:meshHeading | pubmed-meshheading:9060550-... | lld:pubmed |
| pubmed-article:9060550 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9060550 | pubmed:articleTitle | Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial. | lld:pubmed |
| pubmed-article:9060550 | pubmed:affiliation | University of Southern California School of Medicine, Los Angeles 90033, USA. hornor@hsc.usc.edu | lld:pubmed |
| pubmed-article:9060550 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9060550 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9060550 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:9060550 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:9060550 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
